Confirming your payment

Skip to content

Competency-Based Questions (CBQ) · Question 3 of 80

A child with ADA deficiency is treated by gene therapy.

Question 31 markMCQMedium

A child with ADA deficiency is treated by gene therapy. Lymphocytes from her blood are grown in culture, a functional ADA cDNA is introduced into them using a retroviral vector, and the cells are returned to her. Her immune function improves.

Several months later, tests show that her immune function is falling again, although the treatment had worked as planned. What is the most likely explanation, and what does it mean for her treatment?

Select your answer
  • (A) Her immune system has removed the ADA cDNA from the lymphocytes, so she can now be treated only by bone marrow transplantation.

  • (B) The engineered lymphocytes are not immortal and are dying out, so she needs periodic infusion of genetically engineered lymphocytes.

    Correct answer
  • (C) The retroviral vector has changed the functional ADA cDNA back into the deleted form, so the therapy cannot be repeated.

  • (D) Lymphocytes cannot express a gene introduced from outside, so the early improvement was not due to the therapy and it should be stopped.